Radiopharm Theranostics Ltd Initial Statement of Beneficial Ownership
Radiopharm Theranostics Ltd Managing Director and CEO Riccardo Canevari has filed a Form 3 reporting his initial ownership position.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Radiopharm Theranostics Ltd Managing Director and CEO Riccardo Canevari has filed a Form 3 reporting his initial ownership position. The filing shows direct ownership of 22,679,986 Ordinary Shares, along with multiple option awards over additional Ordinary Shares at exercise prices ranging from $0.025 to $0.60 per share and expirations between 2026 and 2030.
Footnotes state that significant blocks of options granted in 2023, 2024 and 2025 will vest in stages on July 1 of 2026, 2027 and 2028, provided Mr. Canevari remains a Director on those dates.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (3)
- F1. Granted on December 01, 2023 and will vest on July 1, 2026 provided Mr. Canevari is still a Director on such dates.
- F2. Granted on December 16, 2024. 18,416,762 options will vest on July 1, 2026 and 18,416,762 options will vest on July 1, 2027 provided Mr. Canevari is still a Director on such dates.
- F3. Granted on December 12, 2025. 24,776,855 options will vest on July 1, 2026, 24,776,855 options will vest on July 1, 2027 and 24,784,290 options will vest on July 1, 2028 provided Mr. Canevari is still a Director on such dates.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Radiopharm (RADX) Form 3 filing by Riccardo Canevari show?
What option grants are reported for Radiopharm (RADX) CEO Riccardo Canevari?
When do Riccardo Canevari’s Radiopharm (RADX) options vest according to the Form 3?
What are the lowest and highest exercise prices of Radiopharm (RADX) options held by Riccardo Canevari?
AI-generated analysis. How Rhea-AI works. Not financial advice.
